| Biological Sciences | Lifetime | 58 | US 35 | 99.99 |
| Biological Sciences | 2021-2025 | 993 | US 232 | 98.90 |
| Cancer Research | Lifetime | 1 | US 1 | 99.99 |
| Molecular Biology | Lifetime | 78 | US 57 | 99.97 |
| Nutrition and Dietetics | Lifetime | 56 | US 26 | 99.70 |
| Oncology | Lifetime | 126 | US 68 | 99.79 |
| Immunology | Lifetime | 118 | US 72 | 99.77 |
| Epidemiology | Lifetime | 975 | US 496 | 98.68 |
| Cell Biology | Lifetime | 935 | US 506 | 93.46 |
| Hepatology | Lifetime | 767 | US 283 | 85.71 |
| Epidemiology | 2021-2025 | 305 | US 105 | 97.50 |
| Immunology | 2021-2025 | 193 | US 61 | 95.73 |
| Molecular Biology | 2021-2025 | 781 | US 216 | 95.69 |
| Cancer Research | 2021-2025 | 260 | US 92 | 85.52 |
| Oncology | 2021-2025 | 849 | US 359 | 85.61 |
| Cytokine Signaling Pathways and Interactions | Lifetime | 1 | US 1 | 100.00 |
| Immune Response and Inflammation | Lifetime | 3 | US 2 | 99.99 |
| NF-κB Signaling Pathways | Lifetime | 1 | US 1 | 100.00 |
| interferon and immune responses | Lifetime | 3 | US 2 | 99.93 |
| Immune cells in cancer | Lifetime | 8 | US 2 | 99.89 |
| Trace Elements in Health | Lifetime | 7 | US 6 | 99.85 |
| Ubiquitin and proteasome pathways | Lifetime | 10 | US 9 | 99.91 |
| Melanoma and MAPK Pathways | Lifetime | 8 | US 4 | 99.89 |
| Protein Kinase Regulation and GTPase Signaling | Lifetime | 16 | US 11 | 99.80 |
| Inflammasome and immune disorders | Lifetime | 25 | US 9 | 99.50 |
| Heavy Metal Exposure and Toxicity | Lifetime | 47 | US 26 | 99.46 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 143 | US 83 | 99.63 |
| Cell death mechanisms and regulation | Lifetime | 44 | US 22 | 99.58 |
| RNA Research and Splicing | Lifetime | 202 | US 128 | 99.22 |
| Cancer-related Molecular Pathways | Lifetime | 154 | US 92 | 99.30 |
| Genomics, phytochemicals, and oxidative stress | Lifetime | 68 | US 31 | 99.01 |
| Retinoids in leukemia and cellular processes | Lifetime | 76 | US 46 | 98.98 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 80 | US 48 | 99.22 |
| Liver Disease Diagnosis and Treatment | Lifetime | 600 | US 198 | 99.22 |
| Endoplasmic Reticulum Stress and Disease | Lifetime | 163 | US 90 | 98.61 |
| RNA regulation and disease | Lifetime | 138 | US 71 | 98.44 |
| Cancer, Hypoxia, and Metabolism | Lifetime | 578 | US 280 | 98.47 |
| Adipokines, Inflammation, and Metabolic Diseases | Lifetime | 320 | US 141 | 98.51 |
| Iron Metabolism and Disorders | Lifetime | 310 | US 149 | 97.87 |
| Inflammatory Biomarkers in Disease Prognosis | Lifetime | 243 | US 46 | 95.10 |
| Signaling Pathways in Disease | Lifetime | 287 | US 150 | 96.86 |
| Growth Hormone and Insulin-like Growth Factors | Lifetime | 721 | US 312 | 96.97 |
| Natural product bioactivities and synthesis | Lifetime | 758 | US 90 | 96.92 |
| Estrogen and related hormone effects | Lifetime | 975 | US 557 | 96.93 |
| Nuclear Receptors and Signaling | Lifetime | 229 | US 109 | 96.59 |
| Phagocytosis and Immune Regulation | Lifetime | 358 | US 147 | 94.58 |
| Liver physiology and pathology | Lifetime | 660 | US 204 | 95.38 |
| Protein Degradation and Inhibitors | Lifetime | 743 | US 367 | 95.19 |
| Cancer Mechanisms and Therapy | Lifetime | 609 | US 248 | 94.30 |
| TGF-β signaling in diseases | Lifetime | 393 | US 188 | 94.71 |
| Cancer, Stress, Anesthesia, and Immune Response | Lifetime | 693 | US 303 | 90.00 |
| Pharmacological Effects of Medicinal Plants | Lifetime | 625 | US 96 | 72.28 |
| Inflammasome and immune disorders | 2021-2025 | 28 | US 10 | 98.08 |
| Endoplasmic Reticulum Stress and Disease | 2021-2025 | 30 | US 11 | 96.24 |
| Liver Disease Diagnosis and Treatment | 2021-2025 | 481 | US 114 | 97.73 |
| Immune cells in cancer | 2021-2025 | 211 | US 37 | 95.69 |
| interferon and immune responses | 2021-2025 | 417 | US 87 | 87.98 |
| Immune Response and Inflammation | 2021-2025 | 686 | US 160 | 79.18 |
| Lipid metabolism and biosynthesis | 2021-2025 | 534 | US 111 | 72.52 |
